Healius (ASX:HLS) - Aandelenkoers, Nieuws & Analyse

De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!

HLS Overzicht aandelen

Healius Limited levert diagnostische specialiteiten aan consumenten en artsen in Australië.

HLS fundamentele analyse
Sneeuwvlok Score
Waardering	5/6
Toekomstige groei	3/6
Prestaties in het verleden	0/6
Financiële gezondheid	3/6
Dividenden	0/6

Beloningen

Verhandeld tegen 76.3% onder onze schatting van de reële waarde

De winst zal naar verwachting met 89.02% per jaar groeien

Handelen tegen een goede waarde vergeleken met branchegenoten en branchegenoten

Risicoanalyse

Aandeelhouders zijn het afgelopen jaar verwaterd

Healius Limited Concurrenten

Australian Clinical Labs

ASX:ACL

AU$748.9m

Integral Diagnostics

ASX:IDX

AU$706.4m

Capitol Health

ASX:CAJ

AU$394.3m

Sonic Healthcare

ASX:SHL

AU$13.1b

Prijsgeschiedenis en prestaties

Overzicht van alle hoogtepunten, veranderingen en prijsdalingen voor Healius
Historische aandelenkoersen
Huidige aandelenkoers	AU$1.75
52 Week Hoogtepunt	AU$2.30
52 Week Laag	AU$1.08
Bèta	0.73
11 maand verandering	-0.57%
3 maanden verandering	19.11%
1 Jaar Verandering	-20.32%
33 jaar verandering	-63.49%
5 jaar verandering	-42.97%
Verandering sinds IPO	24.64%

Recent nieuws en updates

Recent updates

Rendement voor aandeelhouders

	HLS	AU Healthcare	AU Markt
7D	0.9%	3.8%	1.1%
1Y	-20.3%	-0.7%	17.9%

Rendement versus industrie: HLS presteerde slechter dan de Australian Healthcare -sector, die het afgelopen jaar een rendement van -4.2 % opleverde.

Rendement versus markt: HLS presteerde slechter dan Australian Market, dat het afgelopen jaar een rendement van 17.2 % opleverde.

Prijsvolatiliteit

Is HLS's price volatile compared to industry and market?
HLS volatility
HLS Average Weekly Movement	5.7%
Healthcare Industry Average Movement	5.1%
Market Average Movement	9.0%
10% most volatile stocks in AU Market	17.6%
10% least volatile stocks in AU Market	3.6%

Stabiele aandelenkoers: HLS heeft de afgelopen 3 maanden geen significante prijsvolatiliteit gekend.

Volatiliteit in de loop van de tijd: De wekelijkse volatiliteit ( 6% ) van HLS is het afgelopen jaar stabiel geweest.

Over het bedrijf

Opgericht	Werknemers	CEO	Website
1994	6,994	Paul Anderson	www.healius.com.au

Healius Limited levert diagnostische specialiteiten aan consumenten en artsen in Australië. Het bedrijf is actief in drie segmenten: Pathologie, Beeldvorming en Overige. Het biedt diagnostische beeldvormingsdiensten, particuliere medische laboratoria en pathologiediensten aan.

Healius Limited Samenvatting

Hoe verhouden de winst en inkomsten van Healius zich tot de beurswaarde?
HLS fundamentele statistieken
Marktkapitalisatie	AU$1.27b
Inkomsten(TTM)	-AU$636.00m
Inkomsten(TTM)	AU$1.75b

0.7x

P/S-verhouding

-2.0x

Koers/Winstverhouding

Is HLS overgewaardeerd?

Zie Reële waarde en waarderingsanalyse

Inkomsten en omzet

Belangrijkste winstgevendheidsstatistieken uit het laatste winstverslag (TTM)
HLS resultatenrekening (TTM)
Inkomsten	AU$1.75b
Kosten van inkomsten	AU$1.21b
Brutowinst	AU$541.20m
Overige uitgaven	AU$1.18b
Inkomsten	-AU$636.00m

Laatst gerapporteerde inkomsten

Jun 30, 2024

Volgende inkomensdatum

n.v.t.

Winst per aandeel (EPS)	-0.88
Brutomarge	30.99%
Nettowinstmarge	-36.42%
Schuld/Eigen Vermogen Verhouding	40.4%

Hoe presteerde HLS op de lange termijn?

Bekijk historische prestaties en vergelijking

HLS Overzicht aandelen

Beloningen

Risicoanalyse

Healius Limited Concurrenten

ASX:ACL

AU$748.9m

ASX:IDX

AU$706.4m

ASX:CAJ

AU$394.3m

ASX:SHL

AU$13.1b

Prijsgeschiedenis en prestaties

Recent nieuws en updates

Price target increased by 14% to AU$1.77

Affinity Equity Partners (Australia) Pty Limited entered into a binding agreement to acquire Lumus Imaging from Healius Limited (ASX:HLS) for enterprise value of AUD 965 million.

Price target increased by 8.4% to AU$1.68

Full year 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Healius Limited, Annual General Meeting, Nov 15, 2024

Price target increased by 7.5% to AU$1.51

Recent updates

Price target increased by 14% to AU$1.77

Affinity Equity Partners (Australia) Pty Limited entered into a binding agreement to acquire Lumus Imaging from Healius Limited (ASX:HLS) for enterprise value of AUD 965 million.

Price target increased by 8.4% to AU$1.68

Full year 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Healius Limited, Annual General Meeting, Nov 15, 2024

Price target increased by 7.5% to AU$1.51

Full year 2024 earnings: Revenues exceed analyst expectations

TPG Capital, PEP Reportedly Still Competing for Healius Lumus Imaging

Final Bids Reportedly Expected for Healius

Healius Limited Announces Step Down of Ravi Jeyaraj as Non-Executive Director, Effective 2 August 2024

Macquarie Unit Reportedly in Healius Race

Healius Limited to Report Fiscal Year 2024 Results on Aug 21, 2024

Sonic in the Running for Healius Imaging Business

Private Equity Reportedly Eyes Healius Diagnostic Imaging Unit

High number of new directors

Healius Limited to Report First Half, 2024 Results on Feb 27, 2024

Australian Clinical Labs Limited (ASX:ACL) cancelled the acquisition of Healius Limited (ASX:HLS) from Tanarra Capital Australia Pty Ltd, Perpetual Investment Management Ltd and others.

New minor risk - Shareholder dilution

Interim Non-Executive Independent Chair recently bought AU$81k worth of stock

High number of new directors

Healius Limited Appoints Ravi Jeyaraj as Director

Healius Limited Announces Chair Changes

Healius Limited Announces Chair Changes

Healius Limited has filed a Follow-on Equity Offering in the amount of AUD 187.32 million.

Healius Limited has filed a Follow-on Equity Offering in the amount of AUD 187.32 million.

Healius Limited, Annual General Meeting, Nov 01, 2023

Australian Clinical Labs Limited (ASX:ACL) canceled the acquisition of Healius Limited (ASX:HLS)

Healius Limited Appoints Michael Stanford as Director

Full year 2023 earnings: Revenues miss analyst expectations

Healius Limited to Report Fiscal Year 2023 Results on Aug 30, 2023

Consensus EPS estimates fall by 37%

Consensus EPS estimates fall by 37%

Healius Limited Appoints Jan Van Rooyen as Group Executive, Healius Pathology Effective 1 June 2023

Consensus EPS estimates increase by 34%

Consensus EPS estimates increase by 36%

Consensus EPS estimates increase by 22%

High number of new directors

Consensus EPS estimates increase by 18%

Is Healius Limited (ASX:HLS) Trading At A 50% Discount?

Independent Non Executive Chairman recently bought AU$103k worth of stock

First half 2023 earnings released: AU$0.045 loss per share (vs AU$0.40 profit in 1H 2022)

Consensus EPS estimates increase by 17%

Healius Limited Announces Resignation of Alison Stephenson as Company Secretary

Consensus EPS estimates fall by 21%

At AU$3.07, Is It Time To Put Healius Limited (ASX:HLS) On Your Watch List?

Healius Limited to Report First Half, 2023 Results on Feb 27, 2023

Consensus forecasts updated

Price target decreased to AU$3.23

Consensus EPS estimates fall by 13%

Nexus Hospitals entered into an agreement to acquire Montserrat Healthcare Pty Ltd from Healius Limited (ASX:HLS).

Here's Why Healius (ASX:HLS) Can Manage Its Debt Responsibly

Consensus EPS estimates fall by 27%

QIC Reportedly Set to Clinch Healius Day Hospital Unit for $140 Million Plus

MD, CEO & Director recently sold AU$660k worth of stock

Is Now An Opportune Moment To Examine Healius Limited (ASX:HLS)?

Brookfield Reportedly Drops Out of Race to Buy Healius

Independent Non Executive Director recently bought AU$86k worth of stock

Non Executive & Independent Director recently bought AU$70k worth of stock

MD, CEO & Director exercised options to buy AU$2.2m worth of stock.